Business
Aelis Farma: Availability of the Description of the Share Buyback Program
BORDEAUX, France, June 24, 2025--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025.
About this update from Aelis Farma Sa
[{"type":"text","content":"BORDEAUX, France, June 24, 2025--(BUSINESS WIRE)--Regulatory News:","length":66,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025.","length":333,"tagName":"p"},{"type":"text","content":"Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on May 27, 2025, in its 16th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law.","length":299,"tagName":"p"},{"type":"text","content":"In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 28, 2025, under number D.25-0314.","length":292,"tagName":"p"},{"type":"text","content":"This document is available on the Company's website at: https://www.aelisfarma.com/investors.","length":97,"tagName":"p"},{"type":"text","content":"***","length":3,"tagName":"p","attribs":{}},{"type":"text","content":"About AELIS FARMA","length":17,"tagName":"p"},{"type":"text","content":"Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company’s CEO, when he was the director of the Neurocentre Magendie of INSERM in Bordeaux. By mimicking this natural mechanism, CB1-SSi appear to selectively inhibit the disease-related activity of the CB1 receptor without disrupting its normal physiological activity. CB1-SSi have consequently the potential to provide new safe treatments for several brain and peripheral organ diseases.","length":770,"tagName":"p"},{"type":"text","content":"Aelis Farma currently has two first-i...